Mass Spectrometry-Based Proteomic Discovery of Prognostic Biomarkers in Adrenal Cortical Carcinoma
Adrenal cortical carcinoma (ACC) is an extremely rare disease with a variable prognosis. Current prognostic markers have limitations in identifying patients with a poor prognosis. Herein, we aimed to investigate the prognostic protein biomarkers of ACC using mass-spectrometry-based proteomics. We performed the liquid chromatography–tandem mass spectrometry (LC–MS/MS) using formalin-fixed paraffin-embedded (FFPE) tissues of 45 adrenal tumors. Then, we selected 117 differentially expressed proteins (DEPs) among tumors with different stages using the machine learning algorithm. Next, we conducted a survival analysis to assess whether the levels of DEPs were related to survival. Among 117 DEPs, HNRNPA1, C8A, CHMP6, LTBP4, SPR, NCEH1, MRPS23, POLDIP2, and WBSCR16 were significantly correlated with the survival of ACC. In age- and stage-adjusted Cox proportional hazard regression models, only HNRNPA1, LTBP4, MRPS23, POLDIP2, and WBSCR16 expression remained significant. These five proteins were also validated in TCGA data as the prognostic biomarkers. In this study, we found that HNRNPA1, LTBP4, MRPS23, POLDIP2, and WBSCR16 were protein biomarkers for predicting the prognosis of ACC..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Cancers - 13(2021), 15, p 3890 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Han Na Jang [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Adrenal cortical carcinoma |
|---|
| doi: |
10.3390/cancers13153890 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ00550001X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ00550001X | ||
| 003 | DE-627 | ||
| 005 | 20240412165056.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers13153890 |2 doi | |
| 035 | |a (DE-627)DOAJ00550001X | ||
| 035 | |a (DE-599)DOAJ3ee51c084291410a9292b82e0ed4d7ca | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC254-282 | |
| 100 | 0 | |a Han Na Jang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mass Spectrometry-Based Proteomic Discovery of Prognostic Biomarkers in Adrenal Cortical Carcinoma |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Adrenal cortical carcinoma (ACC) is an extremely rare disease with a variable prognosis. Current prognostic markers have limitations in identifying patients with a poor prognosis. Herein, we aimed to investigate the prognostic protein biomarkers of ACC using mass-spectrometry-based proteomics. We performed the liquid chromatography–tandem mass spectrometry (LC–MS/MS) using formalin-fixed paraffin-embedded (FFPE) tissues of 45 adrenal tumors. Then, we selected 117 differentially expressed proteins (DEPs) among tumors with different stages using the machine learning algorithm. Next, we conducted a survival analysis to assess whether the levels of DEPs were related to survival. Among 117 DEPs, HNRNPA1, C8A, CHMP6, LTBP4, SPR, NCEH1, MRPS23, POLDIP2, and WBSCR16 were significantly correlated with the survival of ACC. In age- and stage-adjusted Cox proportional hazard regression models, only HNRNPA1, LTBP4, MRPS23, POLDIP2, and WBSCR16 expression remained significant. These five proteins were also validated in TCGA data as the prognostic biomarkers. In this study, we found that HNRNPA1, LTBP4, MRPS23, POLDIP2, and WBSCR16 were protein biomarkers for predicting the prognosis of ACC. | ||
| 650 | 4 | |a adrenal cortical carcinoma | |
| 650 | 4 | |a prognosis | |
| 650 | 4 | |a proteomics | |
| 650 | 4 | |a mass spectrometry | |
| 650 | 4 | |a HNRNPA1 | |
| 653 | 0 | |a Neoplasms. Tumors. Oncology. Including cancer and carcinogens | |
| 700 | 0 | |a Sun Joon Moon |e verfasserin |4 aut | |
| 700 | 0 | |a Kyeong Cheon Jung |e verfasserin |4 aut | |
| 700 | 0 | |a Sang Wan Kim |e verfasserin |4 aut | |
| 700 | 0 | |a Hyeyoon Kim |e verfasserin |4 aut | |
| 700 | 0 | |a Dohyun Han |e verfasserin |4 aut | |
| 700 | 0 | |a Jung Hee Kim |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Cancers |d MDPI AG, 2010 |g 13(2021), 15, p 3890 |w (DE-627)DOAJ000006858 |x 20726694 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2021 |g number:15, p 3890 |
| 856 | 4 | 0 | |u https://doi.org/10.3390/cancers13153890 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/3ee51c084291410a9292b82e0ed4d7ca |z kostenfrei |
| 856 | 4 | 0 | |u https://www.mdpi.com/2072-6694/13/15/3890 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2072-6694 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2021 |e 15, p 3890 | ||